CY1124391T1 - Θεραπεια ανθεκτικης σε ιματινιμπη χρονιας μυελογενους λευχαιμιας που εχει τη μεταλλαξη 1457t>c στο bcrabl γονιδιο χρησιμοποιωντας την ενωση μποσουτινιμπη - Google Patents

Θεραπεια ανθεκτικης σε ιματινιμπη χρονιας μυελογενους λευχαιμιας που εχει τη μεταλλαξη 1457t>c στο bcrabl γονιδιο χρησιμοποιωντας την ενωση μποσουτινιμπη

Info

Publication number
CY1124391T1
CY1124391T1 CY20211100693T CY211100693T CY1124391T1 CY 1124391 T1 CY1124391 T1 CY 1124391T1 CY 20211100693 T CY20211100693 T CY 20211100693T CY 211100693 T CY211100693 T CY 211100693T CY 1124391 T1 CY1124391 T1 CY 1124391T1
Authority
CY
Cyprus
Prior art keywords
imatinib
bosutinib
mutation
treatment
resistant chronic
Prior art date
Application number
CY20211100693T
Other languages
English (en)
Inventor
Becker Hewes
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124391(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CY1124391T1 publication Critical patent/CY1124391T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ενώσεις 4-αμινοκινολινο-3-καρβονιτριλίου χρήσιμες για θεραπεία ενός υποκειμένου που έχει θετική σε BcrAbl λευχαιμία που είναι ανθεκτική σε ιματινίμπη.
CY20211100693T 2007-06-01 2021-08-03 Θεραπεια ανθεκτικης σε ιματινιμπη χρονιας μυελογενους λευχαιμιας που εχει τη μεταλλαξη 1457t>c στο bcrabl γονιδιο χρησιμοποιωντας την ενωση μποσουτινιμπη CY1124391T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93265007P 2007-06-01 2007-06-01
EP08769857A EP2152267A2 (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
PCT/US2008/065215 WO2008150957A2 (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Publications (1)

Publication Number Publication Date
CY1124391T1 true CY1124391T1 (el) 2022-07-22

Family

ID=39639071

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100395T CY1115251T1 (el) 2007-06-01 2014-06-03 Θεραπεια λευχαιμιας ανθεκτικης σε ιματινιμπη χρησιμοποιωντας 4-αμινοκινολινο-3-καρβονιτριλια
CY20211100693T CY1124391T1 (el) 2007-06-01 2021-08-03 Θεραπεια ανθεκτικης σε ιματινιμπη χρονιας μυελογενους λευχαιμιας που εχει τη μεταλλαξη 1457t>c στο bcrabl γονιδιο χρησιμοποιωντας την ενωση μποσουτινιμπη

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20141100395T CY1115251T1 (el) 2007-06-01 2014-06-03 Θεραπεια λευχαιμιας ανθεκτικης σε ιματινιμπη χρησιμοποιωντας 4-αμινοκινολινο-3-καρβονιτριλια

Country Status (24)

Country Link
US (1) US11103497B2 (el)
EP (4) EP2478905B1 (el)
JP (3) JP5888853B2 (el)
KR (1) KR101493543B1 (el)
CN (1) CN101686973B (el)
AU (1) AU2008260070B9 (el)
BR (1) BRPI0812355A2 (el)
CA (3) CA2868899C (el)
CL (1) CL2008001577A1 (el)
CY (2) CY1115251T1 (el)
DK (2) DK2478905T3 (el)
ES (2) ES2881391T3 (el)
HK (1) HK1142812A1 (el)
HU (1) HUE055524T2 (el)
IL (1) IL202407A0 (el)
MX (1) MX2009013069A (el)
PA (1) PA8782301A1 (el)
PL (2) PL3002009T3 (el)
PT (2) PT2478905E (el)
RU (1) RU2464026C2 (el)
SI (2) SI3002009T1 (el)
TW (1) TW200908982A (el)
WO (1) WO2008150957A2 (el)
ZA (1) ZA200908480B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2478905B1 (en) * 2007-06-01 2014-05-14 Wyeth LLC Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
SG192769A1 (en) 2011-03-04 2013-09-30 Glaxosmithkline Ip No 2 Ltd Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
BR112015019624A2 (pt) 2013-02-21 2017-07-18 Glaxosmithkline Ip Dev Ltd quinazolinas como inibidores de quinase
KR101733665B1 (ko) 2015-05-06 2017-05-10 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 Ｆ1 또는 Ｒｇ3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
CA3148794A1 (en) * 2019-08-22 2021-02-25 Biohaven Therapeutics Ltd. 4-amino-quinolines/-quinazolines that bind to tdp-43 for the treatment of amyotrophic lateral sclerosis and related disorders
CN115944636A (zh) * 2022-11-01 2023-04-11 华南师范大学 博舒替尼在抑制i-motif结构上的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
PL207720B1 (pl) * 2001-01-25 2011-01-31 Bristol Myers Squibb Co Sposób przygotowania preparatu farmaceutycznego i jego zastosowanie, farmaceutyczny produkt oraz sposób wytwarzania kompozycji farmaceutycznej
US20050202519A1 (en) 2001-10-05 2005-09-15 Christophe Barthe Mutated abl kinase domains
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) * 2003-07-09 2005-01-13 Kane John Richard Method and apparatus for providing access to personal information
WO2005046693A1 (en) * 2003-11-06 2005-05-26 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
DOP2006000093A (es) 2005-04-25 2007-01-31 Pfizer Anticuerpos contra miostatina
EP1896470B1 (en) 2005-05-16 2010-05-26 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
EP1904654A2 (en) 2005-07-15 2008-04-02 Brystol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides
KR101135220B1 (ko) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
US20100029676A1 (en) 2005-11-04 2010-02-04 Sawyers Charles L T315a and f317i mutations of bcr-abl kinase domain
EP2478905B1 (en) 2007-06-01 2014-05-14 Wyeth LLC Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Also Published As

Publication number Publication date
CN101686973A (zh) 2010-03-31
DK2478905T3 (da) 2014-06-30
RU2464026C2 (ru) 2012-10-20
CA2688467C (en) 2015-05-12
JP2016074700A (ja) 2016-05-12
PA8782301A1 (es) 2009-01-23
EP2478905B1 (en) 2014-05-14
MX2009013069A (es) 2010-03-17
BRPI0812355A2 (pt) 2015-01-27
JP2010529038A (ja) 2010-08-26
WO2008150957A3 (en) 2009-08-06
EP2478905A2 (en) 2012-07-25
AU2008260070A1 (en) 2008-12-11
KR20100017983A (ko) 2010-02-16
ZA200908480B (en) 2010-08-25
JP2014111629A (ja) 2014-06-19
RU2009144128A (ru) 2011-07-20
CY1115251T1 (el) 2017-01-04
EP3002009B1 (en) 2021-07-07
CL2008001577A1 (es) 2008-07-25
PT3002009T (pt) 2021-08-02
HUE055524T2 (hu) 2021-11-29
AU2008260070B2 (en) 2011-08-18
WO2008150957A2 (en) 2008-12-11
PL3002009T3 (pl) 2021-12-13
PL2478905T3 (pl) 2014-10-31
EP2777704A2 (en) 2014-09-17
CN101686973B (zh) 2013-06-19
CA2868899C (en) 2017-06-13
CA2688467A1 (en) 2008-12-11
TW200908982A (en) 2009-03-01
CA2964162A1 (en) 2008-12-11
EP3002009A3 (en) 2016-07-06
JP5888853B2 (ja) 2016-03-22
EP2478905A3 (en) 2013-01-16
US11103497B2 (en) 2021-08-31
IL202407A0 (en) 2010-06-30
DK3002009T3 (da) 2021-08-02
ES2881391T3 (es) 2021-11-29
SI3002009T1 (sl) 2021-09-30
EP2152267A2 (en) 2010-02-17
EP2777704A3 (en) 2015-01-21
SI2478905T1 (sl) 2014-07-31
US20080318971A1 (en) 2008-12-25
KR101493543B1 (ko) 2015-02-13
HK1142812A1 (en) 2010-12-17
CA2868899A1 (en) 2008-12-11
EP3002009A2 (en) 2016-04-06
AU2008260070B9 (en) 2012-01-19
CA2964162C (en) 2019-12-31
ES2477567T3 (es) 2014-07-17
PT2478905E (pt) 2014-07-16

Similar Documents

Publication Publication Date Title
CY1124391T1 (el) Θεραπεια ανθεκτικης σε ιματινιμπη χρονιας μυελογενους λευχαιμιας που εχει τη μεταλλαξη 1457t>c στο bcrabl γονιδιο χρησιμοποιωντας την ενωση μποσουτινιμπη
CY1114539T1 (el) Η χρησιμοτητα των ιμιδαζοπυριδαζινοκαρβονιτριλιων ως αναστολεων κινασων
CY1112595T1 (el) Αμιδοφαινοξυινδαζολια χρησιμα ως αναστολεις του c-met
NO20081636L (no) FAP - inhibitorer
BRPI0510177A (pt) heterociclos monocìclicos como inibidores de cinase
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201171367A1 (ru) Винилиндазолильные соединения
UA110338C2 (en) Chemical compounds
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
CY1112691T1 (el) Αναστολεις αντιγραφης ιου ανθρωπινης ανοσοανεπαρκειας
EA201000549A1 (ru) Производные пиперидина и пиперазина
MA32938B1 (fr) Composes organiques
EA201170832A1 (ru) Пуриновые соединения
ATE479673T1 (de) Hemmer der neubildung menschlicher immundefekt- viren
UA107796C2 (en) Tetracyclic compound
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CY1113942T1 (el) Παραγωγα σουλφοναμιδιου πυριμιδινης και τριαζινης σαν αναστολεις υποδοχεα βραδυκινινης β1 (β1r) για τη θεραπεια πονου
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
ATE400567T1 (de) Kinaseinhibitoren
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
EA201400338A1 (ru) Производные аминопиримидина для применения в качестве модуляторов киназной активности
EA201071248A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
EA201101330A1 (ru) Замещенные пиримидины, предназначенные для лечения рака